Sunitinib in pretreated advanced non-small-cell lung carcinoma: A primary result from Asian population

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 578-583

  Gu, Ping ^a   Wang, Hui Min ^a   Wang, Wei Min ^a   Han, Bao Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Asian; Lung neoplasms; Sunitinib

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASIAN; ASTHENIA; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; THYROID FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRROLES;

EID: 79960295130     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9500-9     Document Type: Article

References (17)

1. A Jemal R Siegel E Ward Y Hao J Xu, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 12778165 10.1038/nm0603-669 1:CAS:528:DC%2BD3sXktFOnur4%3D (Pubitemid 36749215)
3. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10647931 10.1016/S0092-8674(00)81683-9 1:CAS:528:DC%2BD3cXks1CktA%3D%3D (Pubitemid 30046295)
4. KJ O'Byrne MI Koukourakis A Giatromanolaki G Cox H Turley, et al. 2000 Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer Br J Cancer 82 1427 1432 10780522 (Pubitemid 30175909)
5. Y Shikada Y Yonemitsu T Koga M Onimaru T Nakano, et al. 2005 Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas Cancer Res 65 7241 7248 16103075 10.1158/0008-5472.CAN-04-4171 1:CAS:528:DC%2BD2MXns1Wrur0%3D (Pubitemid 41161255)
6. DB Mendel AD Laird X Xin SG Louie JG Christensen, et al. 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337 12538485 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D (Pubitemid 36109749)
7. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington 2003 SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 471 478 12748309 1:CAS:528:DC%2BD3sXkvVersbw%3D
8. AM O'Farrell TJ Abrams HA Yuen TJ Ngai SG Louie, et al. 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 3605 12531805 10.1182/blood-2002-07-2307 (Pubitemid 36857948)
9. O Potapova AD Laird MA Nannini A Barone G Li, et al. 2006 Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 Mol Cancer Ther 5 1280 1289 16731761 10.1158/1535-7163.MCT-03-0156 1:CAS:528:DC%2BD28XltVWms74%3D (Pubitemid 43881321)
10. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010.
11. D Castellano XG del Muro JL Perez-Gracia JL Gonzalez-Larriba MV Abrio, et al. 2009 Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population Ann Oncol 20 1803 1812 19549706 10.1093/annonc/mdp067 1:STN:280:DC%2BD1MjhvVeqtg%3D%3D
12. Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, et al. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2009.
13. S Novello GV Scagliotti R Rosell MA Socinski J Brahmer, et al. 2009 Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer Br J Cancer 101 1543 1548 19826424 10.1038/sj.bjc.6605346 1:CAS:528:DC%2BD1MXhtlWmu7fF
14. MA Socinski S Novello JR Brahmer R Rosell JM Sanchez, et al. 2008 Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 650 656 18235126 10.1200/JCO.2007.13. 9303 1:CAS:528:DC%2BD1cXis1alsbs%3D (Pubitemid 351264362)
15. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
16. K Hotta Y Fujiwara K Kiura N Takigawa M Tabata, et al. 2007 Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials J Thorac Oncol 2 402 407 17473655 10.1097/01.JTO.0000268673.95119.c7 (Pubitemid 47181694)
17. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)